Acquired Company
Crown Laboratories completed the acquisition of Revance Therapeutics on 2/6/2025 following a tender offer at $3.65 per share, with the transaction finalized via a second-step merger.
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California. Show more
1222 DEMONBREUN STREET, NASHVILLE, TN, UNITED STATES, 37203, Suite 1001, Tennessee, 37203, USA
Market Cap
381M
52 Wk Range
$0.00 - $0.00
Previous Close
$3.65
Open
$3.65
Volume
N/A
Day Range
$3.65 - $3.65
Enterprise Value
0.00
Cash
58.59M
Avg Qtr Burn
-41.09M
Insider Ownership
8.56%
Institutional Own.
87.45%
Qtr Updated
09/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
DAXXIFY (DaxibotulinumtoxinA) Details Muscle pain, Pain | Approved Quarterly sales | |
DAXXIFY (DaxibotulinumtoxinA) (injection) Details Glabellar lines | Approved Quarterly sales | |
DAXXIFY (DaxibotulinumtoxinA) Details Muscle control disorder, Spasticity, Congenital adrenal hyperplasia | Phase 3 Update | |
DaxibotulinumtoxinA Details Inflammatory disease, Heel Pain | Failed Discontinued |